AGIO Agios Pharmaceuticals, Inc.
AGIO Agios Pharmaceuticals, Inc.
Healthcare · Biotechnology
Market read
POC $27.69 · VWAP $31.03 · +8.4% vs 12m avg buyer
Insiders no data — outside the Form 4 poll — US-filer feed only (foreign filers report via MAR managers'-transactions notices)
Coverage
2 watchlists
AGIO Price Structure
Loading timeframes…
Peers
Every watchlist AGIO belongs to, members best 30-day change first — AGIO highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@biotech-capital-cycle
Reported the quarter ending 2026-06-30: revenue $45M, diluted EPS -$1.69, net income -$101M (SEC filing, revenue corroborated by the desk's provider cache). Across the print the stock moved -14.3% (close before → first close after).
full note →Against street estimates
How AGIO's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
AGIO research tape
2 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.